← Latest news 
Mounjaro sales dip in India as Ozempic price cuts and semaglutide generics surge
Economy
Published on 24 April 2026
Lilly’s blockbuster faces a double hit from cheaper rivals
Mounjaro sales are sliding across India as Novo Nordisk drives a price war for Ozempic and Wegovy and cheaper semaglutide generics gain traction. Eli Lilly says it’s seeing increased competition but remains confident in Mounjaro’s differentiated benefits for users. The shift highlights how rapidly GLP-1 therapy markets are being reshaped by pricing pressure.
- Mounjaro sales downturn linked to intensified pricing competition
- Novo Nordisk cuts prices for Ozempic and Wegovy
- Semaglutide generics are attracting cost-conscious buyers
- Lilly remains optimistic about Mounjaro’s distinct advantages
Read the full story at The Economic Times
This summarization was done by Beige for a story published on 
The Economic Times